194 related articles for article (PubMed ID: 23892220)
1. [Role of androgen in the elderly. Problems of androgen deprivation therapy].
Tsujimura A
Clin Calcium; 2013 Aug; 23(8):1185-90. PubMed ID: 23892220
[TBL] [Abstract][Full Text] [Related]
2. Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients.
Ferreira U; Leitao VA; Denardi F; Matheus WE; Stopiglia RM; Netto NR
Prostate Cancer Prostatic Dis; 2006; 9(1):39-41. PubMed ID: 16276352
[TBL] [Abstract][Full Text] [Related]
3. Complications of androgen deprivation therapy in prostate cancer.
Schwandt A; Garcia JA
Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
[TBL] [Abstract][Full Text] [Related]
4. Androgens and prostate cancer; pathogenesis and deprivation therapy.
Grossmann M; Cheung AS; Zajac JD
Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
6. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
7. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
8. [Role of androgen in the elderly. Clinical androgen replacement therapy for late-onset hypogonadism].
Amano T
Clin Calcium; 2013 Aug; 23(8):1179-84. PubMed ID: 23892219
[TBL] [Abstract][Full Text] [Related]
9. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
Ross RW; Small EJ
J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
12. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
Smith MR
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.
Kim HS; Freedland SJ
Curr Opin Support Palliat Care; 2010 Sep; 4(3):147-52. PubMed ID: 20592607
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy for prostate cancer: effects on hand function.
Soyupek F; Soyupek S; Perk H; Ozorak A
Urol Oncol; 2008; 26(2):141-6. PubMed ID: 18312932
[TBL] [Abstract][Full Text] [Related]
15. Management of side effects of androgen deprivation therapy.
Grossmann M; Zajac JD
Endocrinol Metab Clin North Am; 2011 Sep; 40(3):655-71, x. PubMed ID: 21889727
[TBL] [Abstract][Full Text] [Related]
16. Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma?
Landau D; Tsakok T; Aylwin S; Hughes S
Clin Endocrinol (Oxf); 2012 Feb; 76(2):179-81. PubMed ID: 21951017
[TBL] [Abstract][Full Text] [Related]
17. Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer.
Hashimoto K; Masumori N; Hashimoto J; Takayanagi A; Fukuta F; Tsukamoto T
Jpn J Clin Oncol; 2011 Mar; 41(3):405-10. PubMed ID: 20947624
[TBL] [Abstract][Full Text] [Related]
18. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
19. Role of testosterone in managing advanced prostate cancer.
Rove KO; Debruyne FM; Djavan B; Gomella LG; Koul HK; Lucia MS; Petrylak DP; Shore ND; Stone NN; Crawford ED
Urology; 2012 Oct; 80(4):754-62. PubMed ID: 22795376
[TBL] [Abstract][Full Text] [Related]
20. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy.
Hamilton EJ; Gianatti E; Strauss BJ; Wentworth J; Lim-Joon D; Bolton D; Zajac JD; Grossmann M
Clin Endocrinol (Oxf); 2011 Mar; 74(3):377-83. PubMed ID: 21118287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
